Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 533573 | NSE Symbol : APLLTD | ISIN : INE901L01018 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
22-Jan-2025	03-Feb-2025	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2025 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months ended 31st December 2024 Please find the outcome of the meeting. (As per BSE Announcement Dated on 03/02/2025)
18-Oct-2024	07-Nov-2024	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2024 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2024 The exchange is hereby informed that the Board of Directors in their Meeting held today has approved the Unaudited Financial Results for the Quarter and Half Year ended September, 2024. (As Per BSE Announcement Dated on 07.11.2024)
25-Jul-2024	08-Aug-2024	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2024 The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Unaudited Financial Results for the quarter ended 30th June, 2024. Read less.. (As Per BSE Announcement Dated on 08.08.2024)
18-Apr-2024	09-May-2024	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/05/2024 inter alia to consider and approve 1. Audited Financial Results of the Company for the quarter and financial year ended 31st March 2024. 2. Dividend on equity shares if any for the financial year ended 31st March 2024. Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st April 2024 will re-open 48 hours after the declaration of the financial results The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today Approved the Audited Financial Results for the quarter and financial year ended 31st March, 2024, and Recommended a dividend of Rs. 11/- (550%) per Equity Share (As Per BSE Announcement dated on 09.05.2024)
29-Mar-2024	29-Mar-2024	Change in Directors	The Board of Directors at its Meeting held today has approved the appointment of Mr. Manish Kejriwal (DIN: 00040055) as an Independent Director of the Company for a period of 5 consecutive years w.e.f. 31st March, 2024 subject to the approval of the Members by way of Special resolution proposed to be passed through Postal Ballot.
18-Jan-2024	05-Feb-2024	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2024 inter alia to consider and approve Unaudited Financial Results for the quarter and nine months period ended 31st December 2023 Please find attached herewith the Outcome of Board Meeting. Please find attached herewith the Unaudited Financial results for the quarter and half year ended 31st December, 2023 (As Per BSE Announcement Dated on 05/02/2024)
16-Oct-2023	07-Nov-2023	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter and half year ended 30th September 2023. Please find attached Unaudited Financial Results PLease find attached the Results (As Per BSE Announcement Dated on 07.11.2023)
21-Jul-2023	04-Aug-2023	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023 inter alia to consider and approve Unaudited Financial Results for the quarter ended 30th June 2023 ALEMBIC PHARMACEUTICALS LIMITED has informed BSE about Board Meeting to be held on 04 Aug 2023 to consider financial statements for the period ended June 2023. Financial results. Approved the Unaudited Financial Results for the quarter ended 30th June, 2023. Designated Dr. Onkar Swami Sr. Vice President - Medical Service, as Senior Management Personnel of the Company w.e.f. 5th August, 2023. Please find enclosed the Unaudited Financial Results for the qtr ended 30th June, 2023 (As per BSE Announcement Dated on 04/08/2023)
24-Apr-2023	05-May-2023	Accounts	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 inter alia to consider and approve 1. Audited Financial Results of the Company for the quarter and financial year ended 31st March 2023. 2. Dividend on equity shares if any for the financial year ended 31st March 2023. Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st April 2023 will re-open 48 hours after the declaration of the financial results. Final Dividend & Audited Results (As per BSE Bulletin dated on 24/04/2023) The exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia Approved the Audited Financial Results for the quarter and financial year ended''31st March, 2023. and Recommended a dividend of Rs. 8/- (400%) per Equity Share. With reference to the captioned matter, this is to inform the exchange that based on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company at its meeting held on 5th May, 2023 has approved the appointment of Mr. Jai Diwanji (DIN: 00910410) as an Independent Director of the Company for a period of 5 (five) consecutive years w.e.f. 5th May, 2023, subject to approval of the members by way of a Special Resolution. We hereby declare that Mr. Jai Diwanji is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. (As Per BSE Announcement dated on 05.05.2023)
02-Mar-2023	02-Mar-2023	Others	The Board of Directors ('Board') of Alembic Pharmaceuticals Limited ('Company') at its meeting held today i.e. 2nd March, 2023, has, inter alia, approved the following: (a) Impairment Review of the Capital Work-in-Progress ('CWIP') lying in the books of the Company as on 1st January, 2023. (b) Scheme of Arrangement between the Company and its shareholders.
17-Jan-2023	01-Feb-2023	Quarterly Results	Quarterly Results With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved the Unaudited Financial Results for the quarter and nine months period ended 31st December, 2022. (As per BSE Announcement Dated on 01/02/2023)
31-Oct-2022	11-Nov-2022	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2022 inter alia to consider and approve Unaudited Financial Results for the quarter and half year ended 30th September 2022 With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved the Unaudited Financial Results for the quarter and half year ended 30th September, 2022. (As Per BSE Announcement dated on 11.11.2022)
20-Jul-2022	04-Aug-2022	Quarterly Results	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 inter alia to consider and approve With reference to the captioned matter the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Thursday 4th August 2022 inter-alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June 2022. Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st July 2022 will re-open 48 hours after the declaration of the financial results. ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2022 ,inter alia, to consider and approve With reference to the captioned matter and in continuation to the above referred intimation, the exchange is hereby informed that the Board of Directors of the Company at their meeting scheduled to be held on 4th August, 2022 shall also consider and approve re-classification of the final dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. We request you to kindly take the same on record. (As Per BSE Announcement Dated on 27.07.2022) With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. With reference to the captioned matter, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter alia approved: 1) Unaudited Financial Results for the quarter ended 30th June, 2022. 2) Re-classification of the dividend of Rs. 10/- (500%) per equity share for the financial year 2021-22, recommended by them at their meeting held on 2nd May, 2022, into interim dividend for the financial year 2021-22. Please note that the said interim dividend will be paid to those shareholders whose names appear on the Register of Members as on the Record Date fixed for the purpose i.e. Thursday, 18th August, 2022. No further final dividend for the financial year 2021-22 shall be declared. The time of commencement of the Board Meeting was 12:30 p.m. and the time of conclusion was 3:30 p.m. We request you to kindly take the same on record. (As Per BSE Announcement Dated on 04.08.2022)
20-Apr-2022	02-May-2022	Accounts	ALEMBIC PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2022 inter alia to consider and approve With reference to the captioned matter the exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Monday 2nd May 2022 inter-alia to transact the following business: 1. To consider and approve Audited Financial Results of the Company for the quarter and financial year ended 31st March 2022. 2. To consider and recommend dividend on equity shares if any for the financial year ended 31st March 2022. Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st April 2022 will re-open 48 hours after the declaration of the financial results. Alembic Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 02, 2022, inter alia, has recommended a dividend of Rs. 10/- (500%) per Equity Share having face value of Rs. 2/- each, subject to approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on 02.05.2022)
29-Mar-2022	29-Mar-2022	Scheme of Amalgamation	This is to inform the exchange that pursuant to the approval granted by the Board of Directors at its meeting held on 28th March, 2022, the Company has entered into Share Purchase Agreement with Orbicular Pharmaceutical Technologies Private Limited (Orbicular), joint venture partner in Aleor Dermaceuticals Limited (Aleor) to acquire the 40% stake held by them in Aleor. Pursuant to said acquisition, Aleor becomes a wholly-owned subsidiary of the Company. Further, the Board of Directors of the Company at its adjourned meeting held on 29th March, 2022, on recommendation of the Audit Committee has also considered and approved the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 and rules framed thereunder ('Scheme'). The Board of Directors of the Company at its adjourned meeting held on 29th March, 2022, on recommendation of the Audit Committee has also considered and approved the Scheme of Arrangement in the nature of Amalgamation of Aleor Dermaceuticals Limited ('Transferor Company') with Alembic Pharmaceuticals Limited ('Transferee Company') and their respective shareholders under Sections 230 to 232 of the Companies Act, 2013 and rules framed thereunder ('Scheme').

1 2

LOGIN HERE

Alembic Pharmaceuticals Ltd

Board Meeting